What is Cervical Cancer Diagnostic Tests Market?
Cervical cancer is a type of cancer that occurs in the cells of the cervix, the lower part of the uterus that connects to the vagina. Finding cervical cancer often starts with an abnormal HPV (human papillomavirus) or Pap test result. This will lead to further tests that can diagnose cervical cancer or pre-cancer. In the next stage colposcopy and biopsy are used to further confirm the furthers. The cervical cancer diagnostic test market is witnessing considerable growth in the future due to advancements in computer-guided cervical cancer tests to minimize false-negative tests and increasing the adoption of at-home screening services.
The market study is being classified by Type (Pap Test, HPV Typing Test, Colposcopy, Biopsy and Bimanual Pelvic Examination), by Application (Hospitals, Specialty Clinics, Cancer and Radiation Therapy Centers, Diagnostic Centers, Homecare and Others) and major geographies with country level break-up.
Abbott Laboratories (United States), BD Medical (United States), Roche Molecular Diagnostics (United States), Hologic (United States), Qiagen (Germany), Quest Diagnostics (United States), BioMerieux (France), Cepheid (United States), Arbor Vita (United States), Trovagene (United States) and DaAn Gene (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Delphi Bioscience (Singapore) and Fujirebio Diagnostics (United States).
The increasing cases of Cervical Cancer growing the need for its testing tools in the market. The leading firms are coming with newly enhanced products with technological advancements increasing the competition between rivalries. Mergers and acquisitions have been changing business strategies in the market. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Cervical Cancer Diagnostic Tests market throughout the predicted period.
Segment Analysis
Analyst at AMA have segmented the market study of Global Cervical Cancer Diagnostic Tests market by Type, Application and Region.
On the basis of geography, the market of Cervical Cancer Diagnostic Tests has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Drivers
- Increasing Prevalence of Cervical Cancer
- Technological Advancements in Diagnostic Tools and Screening Procedures
Market Trend
- Increased Adoption of HPV Home Testing Kit
- Approval and Launch of New Test
Restraints
- Stringent Regulatory Guidelines
Opportunities
- Rising Adoption of Cervical Cancer Diagnostic Tests for the Early Detection of Cervical Cancer
- Technological Advances in Diagnosis Processes
Challenges
- Uncertain Reimbursement Scenario
In April 2020 Roche gets FDA endorsement for Cobas HPV test for use on the Cobas 6800/8800 Systems to recognize women in danger for cervical disease, US Food and Drug Administration (FDA) endorsement for the cobas® HPV test for use on the completely computerized, high-throughput cobas® 6800/8800 Systems., and In Nov 2018, QIAGEN N.V. announced the launch of the QIAscreen HPV PCR Test for the detection of 15 recognized high-risk genotypes of human papillomavirus (HPV), the virus considered to be the cause of cervical cancer. The assay includes both screening and genotyping functionality in one assay.
June 2020, in the Journal of the National Cancer Institute, a computer algorithm improved the accuracy and efficiency of cervical cancer screening compared with cytology (Pap test), the current standard for follow-up of women who test positive with primary human papillomavirus (HPV) screening.
Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Cervical Cancer Diagnostic Tests Providers, Cervical Cancer Diagnostic Tests Equipment Manufacturers, Suppliers, and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries
Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase